Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. (MDNAF): 1 pipeline candidate · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.2 months
D/E 0.24 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Medicenna Therapeutics Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$24.7M
Cash
$33.6M
Quarterly Burn
$12.7M
Runway
8.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| mdna11 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
1
Total value held
$200K
| Holder | Shares | Value |
|---|---|---|
| org partners llc | 175,000 | $200K |
Frequently asked questions
How many drug candidates are in Medicenna Therapeutics Corp.'s pipeline?
Medicenna Therapeutics Corp. (MDNAF) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Medicenna Therapeutics Corp.'s lead drug candidate?
Medicenna Therapeutics Corp.'s most advanced tracked candidate is mdna11 (Phase 1/Phase 2) for Advanced Solid Tumor.
What is Medicenna Therapeutics Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Medicenna Therapeutics Corp. has approximately 8.2 months of cash runway.
What is Medicenna Therapeutics Corp.'s market capitalization?
Medicenna Therapeutics Corp.'s market capitalization is approximately $24.7M.
Who is the CEO of Medicenna Therapeutics Corp.?
Dr. Fahar Merchant Ph.D. is the chief executive officer of Medicenna Therapeutics Corp. (MDNAF).
Get the full picture on Medicenna Therapeutics Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.